The original disclosure in Japanese was released on October 21, 2021 at 15:00 (GMT +8)

October 21, 2021
CompanyHeadquarters
Representative
Contact
TelephoneWebsite

Takara Bio Inc. (First Section TSE, code: 4974)
Nojihigashi 7-4-38, Kusatsu, Shiga, Japan
Koichi Nakao, President & CEO
Takuya Kakemi, Executive Officer, Head ofCorporate Management Division(+81)77-565-6970
https://www.takara-bio.co.jp/

Notice of Revision of Financial Forecast
Takara Bio Inc. (Takara Bio), announced the revision of the first half of the consolidated financial forecast forthe fiscal year ending March 31, 2022 (April 1, 2021 – March 31, 2022) that was disclosed on August 3, 2021, as
follows based on a review of current trends in results of operations.

1. Revision of Financial Forecast
Revision of the consolidated forecast for the first half of the fiscal year ending March 2022(April 1, 2021 – September 30, 2021)
Net sales

OperatingprofitOrdinary
profit

Net income
attributable toowners of parent

Net income
per share

Million yen

Million yen

Million yen

Million yen

Yen

Previous forecast (A)29,70011,40011,400

7,900

65.61

Revised forecast (B)31,50014,10014,20010,00083.05

Amount of change (B-A)

1,800

2,700

2,800

2,100-

Percentage of Change (%)

6.1

23.7

24.6

26.6

-

17,393

3,736

3,820

2,274

18.89

(Reference) Results for thefirst half of the previous fiscal
year ended March 31, 2021

2. Reason for the Revision
Net sales of general research reagents, which are on a recovery trend from the impact of the new Coronavirus
pandemic, and products related to the new Coronavirus PCR test are expected to exceed the previously
announced forecast. In addition, gross margins are expected to increase due to such as an improvement in thecost of sales ratio in the CDMO business. As a result, operating profit, ordinary profit, and net income
attributable to owners of the parent are also expected to exceed the previously announced forecasts. Therefore,
the forecast of consolidated financial results for the first half of the current fiscal year has been revised.
We plan to announce our full-year consolidated financial forecast at the time of our announcement of thefirst-half financial results on November 9, 2021 with further consideration.

The original disclosure in Japanese was released on October 21, 2021 at 15:00 (GMT +8)

Forward-Looking Statements
Statements contained in these materials with respect to the Company’s current plans, forecasts, strategies and beliefs thatare not historical facts are forward-looking statements about the further performance of the Company and its consolidated
subsidiaries. These statements are based on management’s assumptions and beliefs in light of information currently
available to it, but are based on a number of assumptions and beliefs derived from information that contains significant
risks and uncertainties. Actual results may differ materially from these forecasts due to various factors. Factors that could
influence actual results include, but are not limited to, economic conditions, especially trends in consumer spending, as
well as exchange rate fluctuations, changes in laws and government systems, pressure from competitors’ prices and productstrategies, declines in selling power of the Company’s existing and new products, disruptions to production, violations of
our intellectual property rights, rapid advances in technology, and unfavorable verdicts in major litigation.